Publication date: Jul 13, 2026
Mac1 is a conserved macrodomain enzyme in the nonstructural protein 3 (Nsp3) of SARS-CoV-2 and is part of the viral replication machinery. Mac1 is a target for small-molecule inhibitors that could ultimately enable new COVID-19 therapeutics to be developed. Here, we report the structure-guided design, synthesis, and Mac1 inhibition profiling of 25 analogues derived from a hit identified through crystallographic fragment screening. The heteroaryl group and scaffold (cis- and trans-cyclopentane and cyclopentene) were varied. Two new approaches to trans-cyclopentanes were developed: MacMillan’s Ir/Ni-mediated photoredox cross-coupling of alcohols and Barluenga-ValdcE9s’ metal-free cross-coupling of sulfonyl hydrazones and boronic acids. X-ray crystal structures of 19 compounds bound to Mac1 were determined to guide the design and to rationalize the observed SAR. A new family of Mac1 inhibitors with benzothiazole or amino benzothiazoles was discovered and characterized, with IC values of 6-8 μM and ligand efficiency values of up to 0. 40.

| Concepts | Keywords |
|---|---|
| Coupling | |
| Cov | |
| Cross | |
| Design | |
| Developed | |
| Guided | |
| Heteroaryl | |
| Inhibitors | |
| Mac1 | |
| Macrodomain | |
| Nsp3 | |
| Ray | |
| Sars | |
| Synthesis | |
| Trans |
Semantics
| Type | Source | Name |
|---|---|---|
| pathway | KEGG | Viral replication |
| disease | MESH | COVID-19 |
| drug | DRUGBANK | BENZOTHIAZOLE |